- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing
© The Author(s). 2016
Received: 1 January 2016
Accepted: 27 May 2016
Published: 24 June 2016
Accumulating evidence suggests that myeloperoxidase (MPO) is involved in atrial remodeling of atrial fibrillation (AF). Statins could reduce the MPO levels in patients with cardiovascular diseases. This study evaluated the effects of atorvastatin on MPO level and atrial remodeling in a rabbit model of pacing-induced AF.
Eighteen rabbits were randomly divided into sham, control and atorvastatin groups. Rabbits in the control and atorvastatin groups were subjected to rapid atrial pacing (RAP) at 600 bpm for 3 weeks, and treated with placebo or atorvastatin (2.5 mg/kg/d), respectively. Rabbits in the sham group did not receive RAP. After 3 weeks of pacing, atrial structural and functional changes were assessed by echocardiography, atrial effective refractory period (AERP) and AF inducibility were measured by atrial electrophysiological examination, and histological changes were evaluated by Masson trichrome-staining. The L-type calcium channel α1c (Cav1.2), collagen I and III, MPO, matrix metalloproteinase (MMP)-2 and MMP-9 were analyzed by real time polymerase chain reaction and/or western blot.
All rabbits were found to have maintained sinus rhythm after 3 weeks of RAP. Atrial burst stimulation induced sustained AF (>30 min) in 5, 4, and no rabbits in the control, atorvastatin, and sham groups, respectively. The AERP shortened and Cav1.2 mRNA level decreased in the control group, but these changes were suppressed in the atorvastatin group. Obvious left atrial enlargement and dysfunction was found in both control and atorvastatin groups. Compared with the control group, these echocardiograhic indices of left atrium did not differ in the atorvastatin group. Prominent atrial fibrosis and increased levels of collagen I and III were observed in the control group but not in the atorvastatin group. The mRNA and protein levels of MPO, MMP-2 and MMP-9 significantly increased in the control group, but these changes were prevented in the atorvastatin group.
Treatment with atorvastatin prevented atrial remodeling in a rabbit model of RAP-induced AF. The reduction of levels of atrial MPO, MMP-2 and MMP-9 may contribute to the prevention of atorvastatin on atrial remodeling.
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, increasing in prevalence with age . It results in serious potential complications, especially stroke and heart failure, and increased mortality . Despite recent advances in pharmacological strategy and radiofrequency ablation, the treatment of AF is still not satisfactory.
In recent years, accumulating evidence suggests that the main mechanisms contributing to the initiation and maintenance of AF are atrial electrical and structural remodeling [3, 4], and myeloperoxidase (MPO) is involved in the associated atrial remodeling [5, 6]. MPO is a major contributor to inflammatory oxidative stress, and catalyzes the generation of reactive species . It is a crucial prerequisite for atrial fibrosis, leading to an increased vulnerability to AF . Patients with AF had higher plasma and atrial MPO levels compared with individuals in sinus rhythm , and high MPO level predicted an increased risk of AF recurrence after catheter ablation .
Statins are widely used in primary and secondary prevention of ischemic heart disease and stroke, because of their lipid-lowering effect. In addition, statins also have anti-inflammatory and antioxidant properties, which may help prevent AF . Recent meta-analyses showed that the use of statins is associated with a decreased risk of AF in patients with sinus rhythm [9, 10]. Some studies also reported that statins could attenuate atrial electrical or structural remodeling in dog and goat AF models [11–14]. However, the molecular mechanism by which statins may prevent AF has not been elucidated. Previous research showed that statins could reduce the MPO levels in patients with cardiovascular diseases [15, 16]. This study was designed to investigate the potential effects of atorvastatin on MPO level and atrial remodeling in a rabbit model of pacing-induced AF.
Eighteen male New Zealand white rabbits (2.5–3.0 kg) were randomly allocated to sham (n = 6), control (n = 6) and atorvastatin (n = 6) groups. All rabbits were anesthetized with an intravenous injection of 3 % pentobarbital sodium (30 mg/kg). The left thoracic cavity was opened via 2–4 intercostals, and then the heart was exposed by a dilator. One thin silicon plaque containing two pairs of electrodes was implanted in the free wall of the left atrial appendage. One pair was connected to a pacemaker (Fudan University, Shanghai, China) implanted in a subcutaneous pocket on the back of the rabbit. The other pair was tunneled subcutaneously and exposed at the back of the rabbit, and used for electrophysiological measurements . When surgery was completed, rabbits were given antibiotics and allowed to recover for one week. After that, rabbits in the control and atorvastatin groups were subjected to rapid atrial pacing (RAP) at 600 beats/min for 3 weeks, meanwhile they received oral placebo or atorvastatin (2.5 mg/kg/day), respectively. Rabbits in the sham group did not receive RAP.
Electrocardiogram (ECG) was recorded before and after the pacing. During the period of RAP, ECG was measured every day to ensure that the pacemakers were working properly.
The atrial effective refractory period (AERP) was measured at a basic cycle length of 150 ms. Eight basic stimuli (S1) were followed by a premature stimulus (S2). The S1-S2 intervals were decreased in 10 ms steps until S2 failed to produce an atrial response, then increased by 10 ms, and decreased in 2 ms steps until S2 capture failure. The longest S1-S2 interval that failed to capture was defined as the AERP150 [11, 17].
AF was induced with a train of 10Hz, 2 ms stimuli to the left atrium at four times threshold current  and was induced ten times in each rabbit. AF was considered sustained if it persisted for more than 30 min.
The structure and function of the left atrium (LA) and left ventricle (LV) were assessed by transthoracic echocardiographic examinations (Philips IU 22, Washington, USA). LV end diastolic diameter (LVEDD) and end systolic diameter (LVESD), LV ejection fraction (LVEF), LA diameter (LAD), LA maximal volume (LAVmax) and minimal volume (LAVmin) were measured before and after the pacing. The volume measurements were calculated from apical 4- and 2-chamber views using the biplane area-length method. LAVmax was recorded immediately before the mitral valve opening and LAVmin was recorded at mitral valve closure. LA ejection fraction (LAEF) was calculated according to the formula: (LAVmax- LAVmin)/LAVmax × 100 % .
At the end of the experiments, all rabbits were euthanized and then the LA free wall tissues were quickly removed. Formalin-fixed paraffin-embedded tissues were stained with Masson’s trichrome. The collagen fibers were marked with blue, while the cardiomyocytes were marked with red. Fibrous tissue areas were quantified using Image Pro Plus 6.0 software (Media Cybernetics, Maryland, USA) .
Western blot analysis
The total proteins were purified from the LA free wall, separated by 10 % SDS-PAGE, and then transferred onto a polyvinylidene difluoride membrane. This was blocked at room temperature for 1 h in Tris-buffered saline with 0.5 % Tween 20 containing 5 % skim milk and probed with primary antibodies overnight at 4 °C.
The following primary antibodies were independently used to detect specific proteins: collagen I (1:500 dilution, Bioworld, USA), collagen III (1:500 dilution, Bioworld, USA), MPO (1:200 dilution, Santa Cruz, USA), matrix metalloproteinase (MMP)-2 (1:500 dilution, ProteinTech, USA), MMP-9 (1:500 dilution, ProteinTech, USA), and tissue inhibitors of metalloproteinase (TIMP)-1 (1:1000 dilution, Abcam, USA). An antibody against β-actin (1:1000 dilution, ProteinTech, USA) was used as an internal control.
Horseradish peroxidase-conjugated anti-goat (1:10000 dilution, Beyotime, China) or anti-mouse (1:10000 dilution, ZSGB Biological Company, China) IgGs were used to bind the primary antibodies. Protein bands on Western blots were visualized using an enhanced chemiluminescence detection system (Santa Cruz, USA). Relative band densities of proteins in Western blots were normalized against β-actin.
Real time polymerase chain reaction (RT-PCR)
RNA primer sequences
Quantitative data are expressed as mean ± standard deviation. Comparisons of data before and after RAP were analyzed by t-test. Multiple-group comparisons were analyzed using one-way analysis of variance. SPSS 19.0 software (IBM-SPSS, Chicago, USA) was used in the statistical analysis. P < 0.05 is considered statistically significant.
Atrial burst stimulation induced sustained AF in 5 out of 6 (83 %) rabbits in the control group, 4 of 6 (67 %) in the atorvastatin group, but none in the sham group (Fig. 1b).
Before RAP, no significant difference in the AERP150 was observed among the 3 groups (sham group: 104 ms ± 5 ms, control group: 105 ms ± 5 ms, atorvastatin group: 103 ms ± 4 ms). After 3 weeks of RAP, the AERP150 of the control group (76 ± 4 ms) was significantly shorter than that of the sham group (103 ± 4 ms, P < 0.05). The AERP150 of the atorvastatin group was also shortened (85 ± 5 ms), but the RAP-induced reduction was reversed to some extent compare with the control group (76 ± 4 ms, P < 0.05) (Fig. 1c).
Changes of echocardiographic indices before and after RAP
9.73 ± 0.69
0.54 ± 0.08
0.27 ± 0.05
48.82 ± 4.48
8.46 ± 0.99
13.68 ± 1.77
72.20 ± 3.65
4 weeks post-operation
9.85 ± 0.61
0.53 ± 0.07
0.28 ± 0.05
47.59 ± 6.05
8.44 ± 0.91
13.53 ± 1.53
71.75 ± 2.81
9.58 ± 0.62
0.52 ± 0.09
0.26 ± 0.03
49.42 ± 3.39
8.39 ± 0.88
13.37 ± 1.23
71.18 ± 4.46
3 weeks after RAP
16.02 ± 0.84*, **
1.94 ± 0.28*, **
1.40 ± 0.18*, **
27.77 ± 4.18*, **
8.77 ± 0.64
13.35 ± 1.28
67.47 ± 2.92
9.75 ± 0.56
0.55 ± 0.10
0.28 ± 0.05
49.31 ± 5.48
8.37 ± 0.94
13.58 ± 1.32
71.42 ± 3.15
3 weeks after RAP
15.53 ± 0.62*, **
1.78 ± 0.24*, **
1.29 ± 0.17*, **
27.32 ± 3.70*, **
8.78 ± 0.78
13.64 ± 1.22
68.50 ± 5.34
Atrial structural remodeling
Atrial ion-channel remodeling
Levels of MPO, MMP-2, MMP-9 and TIMP-1 in the LA
The present data demonstrated that in the rabbit model of RAP-induced AF, atorvastatin suppressed AERP shortening and atrial interstitial fibrosis induced by RAP, but had no effect on RAP-induced atrial enlargement and dysfunction. In addition, atorvastatin suppressed the down-regulation of Cav1.2 mRNA, and prevented the increase in the levels of collagen I and III, MPO, MMP-2 and MMP-9 induced by RAP.
The main mechanisms contributing to AF initiation and maintenance are atrial electrical and structural remodeling. In recent years, several animal models of AF [11–13, 20, 21] have been developed to investigate the molecular mechanism contributing to atrial remodeling. Among them, the dog [11, 14, 20] and rabbit [17, 19, 21] AF models induced by RAP are widely used. However, if atrioventricular block is not performed, dogs will develop significant LV dysfunction induced by RAP , whereas rabbits will not . It is well known that LV dysfunction will subject the LA to a pressure overload, leading to atrial enlargement and electrical instability . Therefore, in the present study we chose rabbits to create an AF animal model to avoid the influence of LV dysfunction on atrial remodeling.
Effects of atorvastatin on atrial structural remodeling
Atrial structural remodeling is characterized by atrial enlargement and interstitial fibrosis [4, 23], and has been considered as a major contributor to AF . LA enlargement has been identified as an independent risk factor for AF. For example, patients are more prone to paroxysmal AF if they have an increased LAD . Larger LA volume before cardioversion is associated with higher risks of AF recurrence . LA enlargement also significantly correlates with atrial fibrosis, which serves as a crucial substrate in the formation of AF and is difficult to reverse . Increased fibrosis has been observed in the atrium of animal models [20, 21] and patients with AF . It is characterized by enhanced deposition of matrix collagen proteins, leads to inhomogeneous atrial electrical conduction, and gives rise to electrical reentry circuits which result in AF .
In our study, after 3 weeks of RAP, rabbits showed significant atrial structural remodeling. The pacing time of our rabbit AF model is relatively short compared with the previous canine AF model [14, 20], but rabbits have already had obvious atrial enlargement and interstitial fibrosis. In the previous canine AF model, after 4–6 weeks of RAP, LA volumes were nearly 2 times that at baseline [14, 28], and atrial fibrosis of the control group was nearly 9–10 times that of the sham group [20, 28]. In our model, after 3 weeks of RAP, LA volumes were nearly 4 times that at baseline, and atrial fibrosis of the control group was nearly 7 times that of the sham group. The obvious atrial structural remodeling contributed to a marked increase in AF inducibility. After 3 weeks of RAP, although all rabbits in the control group remained sinus rhythm when pacemakers were deactivated, atrial burst pacing induced sustained AF almost in all rabbits.
Our study showed that atorvastatin treatment could not prevent AF susceptibility and atrial enlargement and dysfunction, but could prevent atrial interstitial fibrosis and collagen protein expression levels. These results are not completely consistent with the previous research , which showed that statins could not prevent AF susceptibility, but could prevent atrial dilatation and fibrosis in a canine AF model induced by 6 weeks of RAP. The different effects of statins on atrial dilatation may be attributed to different AF animal models and drug intervention time. In addition, LA volumes after RAP were only 2 times that at baseline in the previous research, while in our study these were nearly 4 times that at baseline, which may predict more serious LA enlargement, so is hard to reverse.
The metabolism of extracellular matrix is regulated by MMPs and their inhibitors, the TIMPs . Among many kinds of MMPs and TIMPs, MMP-2 and MMP-9 are key factors leading to atrial fibrosis in AF [5, 30, 31], while TIMP-1 is a major inhibitor of MMP activity in AF tissues . MPO, a major contributor to inflammatory oxidative stress, also has an important role in AF. It could promote MMP expression and activation by catalyzing the generation of reactive species, and subsequently resulted in atrial fibrosis and AF [5, 6]. Previous research showed that patients with AF had higher plasma and atrial MPO levels compared with individuals in sinus rhythm , and high MPO levels predicted an increased risk of AF recurrence after catheter ablation . In addition, MPO-deficient mice were protected from atrial fibrosis and AF vulnerability induced by angiotensin II, and atrial MMP-2 and MMP-9 levels were profoundly reduced. However, if administrated with recombinant MPO, these MPO-deficient mice would develop a similar degree of atrial fibrosis as that observed in MPO-infused wild type mice .
Many studies showed that statins, by their anti-inflammatory and antioxidant properties, could reduce the levels of plasma MPO in patients with cardiovascular diseases [15, 16], and inhibit MPO mRNA expression in macrophages . In addition, statins also could inhibit secretion of MMP-2 and MMP-9 , and down-regulate their expression levels [34, 35]. In our study, the levels of MPO, MMP-2, MMP-9 and TIMP-1 were significantly increased after RAP. Atorvastatin treatment could suppress the increased levels of MPO, MMP-2 and MMP-9, especially MPO and MMP-9, but could not suppress the increased level of TIMP-1. These may be the potential mechanisms by which statins prevent atrial structural remodeling of AF.
In addition, peroxisome proliferator-activated receptor-gamma (PPARγ) is also involved in atrial remodeling and AF. Recent studies showed that PPARγ was decreased in elderly AF patients  and hypertensive AF patients , while PPARγ agonists could inhibit atrial remodeling in AF models [38, 39] and prevent new onset AF in patients with non-insulin dependent diabetes . Statins could activate PPARγ and enhance its expression [41, 42] by their anti-inflammatory and antioxidant properties. Therefore, whether the modulation of statins on PPARγ is involved in the molecular mechanisms of the prevention of statins against atrial remodeling in our rabbit model of AF is still a question and would be investigated in our future study.
Effects of atorvastatin on atrial electrical remodeling
Atrial electrical remodeling is characterized by ion channel dysfunction , which creates a re-entry-prone substrate. In our study, 3 weeks of RAP caused AERP shortening and down-regulation of Cav1.2 and Kv4.3 mRNA. This is consistent with previous research using dog AF models [11, 20, 21]. In the present study, atorvastatin treatment could partially suppress AERP shortening and Cav1.2 mRNA down-regulation, but had no effect on Kv4.3 mRNA down-regulation. Many studies have proved that atrial electrical remodeling was promoted by inflammation and oxidative stress, while could be reversed by statins [8, 11, 13, 43]. As mentioned above, atorvastatin treatment suppressed the increased level of MPO, which is a major contributor to inflammatory oxidative stress. Therefore, our study suggests that statins may prevent electrical remodeling, and the reduced atrial MPO level may contribute to the prevention of statins on this process.
The present study demonstrated that atorvastatin treatment prevented atrial remodeling in a rabbit model of RAP-induced AF. The reduction of levels of atrial MPO, MMP-2 and MMP-9 may contribute to the prevention of atorvastatin on atrial remodeling. These findings provide pharmacological evidence for the clinical use of statins in the treatment of AF.
The sample size was relatively small, and the duration of RAP was relatively short. In this study, we only measured the levels of MPO, MMP-2 and MMP-9, but did not measure their enzymatic activity in the atrium. In addition, we did not investigate whether the preventive effects of atorvastatin on atrial remodeling of AF were dose-dependent, and did not conduct detailed molecular study in cardiac tissue as well as extracellular matrix remodeling due to some methodological limitations. Last but importantly, we did not show the causality between the inhibition of MPO by statins and the suppressed atrial remodeling. MPO might be just a concomitantly induced factor rather than a key mediator in our model.
AERP, atrial effective refractory period; AF, atrial fibrillation; Cav1.2, L-type calcium channel α1c; ECG, electrocardiogram; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Kv4.3, transient outward potassium channel; LA, left atrium; LAEF, left atrial ejection fraction; LAVmax, left atrial maximal volume; LAVmin, left atrial minimal volume; LV, left ventricle; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; MMP, matrix metalloproteinase; MPO, myeloperoxidase; PPARγ, peroxisome proliferator-activated receptor-gamma; RAP, rapid atrial pacing; RT-PCR, real time polymerase chain reaction; TIMP, tissue inhibitors of metalloproteinase
The authors thank Ronghong Jiao and Chao Wang for their excellent technical support.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.
QY participated in the design, performed the experiment, collected the data, performed statistical analyses and drafted the manuscript. XYQ participated in the design, performed statistical analyses and helped to draft the manuscript. YD and YXL performed the experiment, collected the data and performed statistical analyses. XLS and XH performed the experiment and collected the data. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH publication No. 85–23, revised 1996), and were approved by the Animal Experimentation Ethics Committee of Hebei Medical University.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101–98.View ArticlePubMedGoogle Scholar
- Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.View ArticlePubMedGoogle Scholar
- Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265–325.View ArticlePubMedGoogle Scholar
- Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335–45.View ArticlePubMedGoogle Scholar
- Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Friedrichs K, Baldus S, Klinke A. Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO. Front Physiol. 2012;3:214.View ArticlePubMedPubMed CentralGoogle Scholar
- Li SB, Yang F, Jing L, Ma J, Jia YD, Dong SY, et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J Investig Med. 2013;61:722–7.View ArticlePubMedGoogle Scholar
- Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal. 2014;20:1268–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28:7–18.View ArticlePubMedGoogle Scholar
- Yang Q, Qi X, Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2014;14:99.View ArticlePubMedPubMed CentralGoogle Scholar
- Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313–9.View ArticlePubMedGoogle Scholar
- Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74:75–84.View ArticlePubMedGoogle Scholar
- Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011;124:1107–17.View ArticlePubMedGoogle Scholar
- Li J, Xia W, Feng W, Qu X. Effects of rosuvastatin on serum asymmetric dimethylarginine levels and atrial structural remodeling in atrial fibrillation dogs. Pacing Clin Electrophysiol. 2012;35:456–64.View ArticlePubMedGoogle Scholar
- Ndrepepa G, Braun S, Schomig A, Kastrati A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol. 2011;100:327–33.View ArticlePubMedGoogle Scholar
- Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis. 2010;210:194–8.View ArticlePubMedGoogle Scholar
- Yu J, Li W, Li Y, Zhao J, Wang L, Dong D, et al. Activation of beta(3)-adrenoceptor promotes rapid pacing-induced atrial electrical remodeling in rabbits. Cell Physiol Biochem. 2011;28:87–96.View ArticlePubMedGoogle Scholar
- Fu H, Liu C, Li J, Zhou C, Cheng L, Liu T, et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J. 2013;20:59–67.View ArticlePubMedGoogle Scholar
- Zhao Y, Gu TX, Zhang GW, Liu HG, Wang C. Losartan affects the substrate for atrial fibrillation maintenance in a rabbit model. Cardiovasc Pathol. 2013;22:383–8.View ArticlePubMedGoogle Scholar
- Nakatani Y, Nishida K, Sakabe M, Kataoka N, Sakamoto T, Yamaguchi Y, et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:582–8.View ArticlePubMedGoogle Scholar
- He X, Gao X, Peng L, Wang S, Zhu Y, Ma H, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin ii type 1 receptor-specific arkadia-mediated downregulation of smad7. Circ Res. 2011;108:164–75.View ArticlePubMedGoogle Scholar
- Weiss JN, Qu Z, Chen PS, Lin SF, Karagueuzian HS, Hayashi H, et al. The dynamics of cardiac fibrillation. Circulation. 2005;112:1232–40.View ArticlePubMedGoogle Scholar
- Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264–74.View ArticlePubMedGoogle Scholar
- Cui Q, Zhang W, Wang H, Sun X, Yang H, Meng X, et al. Left and right atrial size and the occurrence predictors in patients with paroxysmal atrial fibrillation. Int J Cardiol. 2008;130:69–71.View ArticlePubMedGoogle Scholar
- Marchese P, Bursi F, Delle Donne G, Malavasi V, Casali E, Barbieri A, et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr. 2011;12:214–21.View ArticlePubMedGoogle Scholar
- Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.View ArticlePubMedGoogle Scholar
- Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–4.View ArticlePubMedGoogle Scholar
- Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol. 2010;159:1584–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci. 2008;65:1489–508.View ArticlePubMedGoogle Scholar
- de Jong S, van Veen TA, de Bakker JM, Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis. J Cardiovasc Pharmacol. 2011;57:522–35.View ArticlePubMedGoogle Scholar
- Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008;45:742–53.View ArticlePubMedGoogle Scholar
- Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun. 2005;331:442–51.View ArticlePubMedGoogle Scholar
- Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, −2, −3, and −9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769–75.View ArticlePubMedGoogle Scholar
- Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:547–54.View ArticlePubMedGoogle Scholar
- Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol. 2010;145:438–43.View ArticlePubMedGoogle Scholar
- Lin Q, Jia L, Sun Y. A pilot study of circulating ppar-gamma receptor protein in elderly patients with atrial fibrillation. Arch Med Sci. 2012;8:471–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen X, Bing Z, He J, Jiang L, Luo X, Su Y, et al. Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. Clin Cardiol. 2009;32:337–45.View ArticlePubMedGoogle Scholar
- Liu T, Zhao H, Li J, Korantzopoulos P, Li G. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiovasc Ther. 2014;32:178–83.View ArticlePubMedGoogle Scholar
- Gu J, Liu X, Wang QX, Guo M, Liu F, Song ZP, et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models. J Mol Cell Cardiol. 2013;65:1–8.View ArticlePubMedGoogle Scholar
- Chao TF, Leu HB, Huang CC, Chen JW, Chan WL, Lin SJ, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol. 2012;156:199–202.View ArticlePubMedGoogle Scholar
- Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Eur J Pharmacol. 2010;649:255–62.View ArticlePubMedGoogle Scholar
- Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa Y, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:1442–51.View ArticlePubMedGoogle Scholar
- Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230–43.View ArticlePubMedGoogle Scholar